5,6-Dihydro-5-methyluracil
Based on 3 publication(s) in Google Scholar
5,6-Dihydro-5-methyluracil (Dihydrothymine) is an intermediate breakdown product of Thymine (HY-W010450). 5,6-Dihydro-5-methyluracil can be used as a marker of DNA damage. 5,6-Dihydro-5-methyluracil can be used for the research of COVID-19.
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 696-04-8
- Formula: C5H8N2O2
- Molecular Weight:128.13
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) 5,6-Dihydro-5-methyluracil
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
5,6-Dihydro-5-methyluracil X-irradiation of d(TpA) in anaerobic aqueous solution produces 5,6-dihydrothymine-modified d(TpA) as the most abundant lesion[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 696-04-8
-
Appearance Solid
-
Molecular Weight 128.13
-
Formula C5H8N2O2
-
Color White to off-white
-
SMILES
O=C1NC(C(C)CN1)=O
-
Synonyms
Dihydrothymine
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. [Abstract]2024 Aug 12;42(8):1386-1400.e8. PMID: 39137727 -
ACS Omega
Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]2024 Feb 28;9(10):11870-11882. PMID: 38496939 -
J Pharm Biomed Anal
A novel UHPLC-MS/MS approach for simultaneous quantification of pyrimidine metabolites in human biofluids. [Abstract]2025 Nov 15:265:117026. PMID: 40544701
Solvent & Solubility
DMSO : 62.5 mg/mL (487.79 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (16.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (16.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. de Fátima Cobre A, et al. Diagnosis and prognosis of COVID-19 employing analysis of patients' plasma and serum via LC-MS and machine learning. Comput Biol Med. 2022 Jul;146:105659. [Content Brief]
[2]. Dawidzik JB, et al. Dihydrothymine lesion in X-irradiated DNA: characterization at the molecular level and detection in cells. Int J Radiat Biol. 2004;80(5):355-361. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 7.8046 mL | 39.0229 mL | 78.0457 mL | 195.1143 mL |
| 5 mM | 1.5609 mL | 7.8046 mL | 15.6091 mL | 39.0229 mL | |
| 10 mM | 0.7805 mL | 3.9023 mL | 7.8046 mL | 19.5114 mL | |
| 15 mM | 0.5203 mL | 2.6015 mL | 5.2030 mL | 13.0076 mL | |
| 20 mM | 0.3902 mL | 1.9511 mL | 3.9023 mL | 9.7557 mL | |
| 25 mM | 0.3122 mL | 1.5609 mL | 3.1218 mL | 7.8046 mL | |
| 30 mM | 0.2602 mL | 1.3008 mL | 2.6015 mL | 6.5038 mL | |
| 40 mM | 0.1951 mL | 0.9756 mL | 1.9511 mL | 4.8779 mL | |
| 50 mM | 0.1561 mL | 0.7805 mL | 1.5609 mL | 3.9023 mL | |
| 60 mM | 0.1301 mL | 0.6504 mL | 1.3008 mL | 3.2519 mL | |
| 80 mM | 0.0976 mL | 0.4878 mL | 0.9756 mL | 2.4389 mL | |
| 100 mM | 0.0780 mL | 0.3902 mL | 0.7805 mL | 1.9511 mL |
5,6-Dihydro-5-methyluracil Related Classifications
HY-N6787 Related Classifications
Powered by Bioz